Clinical Trial: A IIT Study of 177Lu-DOTA-SNA040

U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07595237) titled 'A IIT Study of 177Lu-DOTA-SNA040' on Nov. 04, 2025.

Brief Summary: This clinical trial is a single-center, open-label, non-randomized, first-in-human (FIH), dose-escalation study evaluating the safety, tolerability, and preliminary efficacy of 177Lu-DOTA-SNA040 in patients with advanced Claudin18.2-positive solid tumors (e.g., gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic cancer, cholangiocarcinoma, etc.) who have disease progression following first-line therapy.

Study Start Date: Nov. 01, 2025

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumors (Such as Gastric Cancer) Advanced Solid Tumors (Such a...